BioCentury | Dec 19, 2019

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

...cancers, Phase II testing for solid tumors. eFFECTOR Therapeutics Inc. has the EIF4A1 inhibitor zotatifin (eFT226...
BioCentury | Jul 29, 2017

Potentiator potential

...eFT508 monotherapy trials and both eFT508 combination trials. It also will begin clinical testing of eFT226...
BioCentury | Jul 24, 2017
Financial News

Effector raises $38.6M in series C

...2H18, Worland said. The company plans to begin clinical testing next year of another candidate, eFT226...
...4A1( EIF4A1) MAP kinase interacting serine-threonine kinase 1 (MKNK1) (MNK1) MAP kinase interacting serine-threonine kinase 2 (MKNK2) (MNK2) eFT226...
Items per page:
1 - 3 of 3